Stimulatory Action of Cyclooxygenase Inhibitors on Hematopoiesis: A Review

Michal Hofer *, Milan Pospíšil, Zuzana Hoferová, Lenka Weiterová and Denisa Komůrková

Laboratory of Experimental Hematology, Institute of Biophysics, v.v.i., Academy of Sciences of the Czech Republic, Královopolská 135, CZ-61265 Brno, Czech Republic; E-Mails: ksoucek@ibp.cz (M.P.); hoferovaz@centrum.cz (Z.H.); weiterova@seznam.cz (L.W.); komurkovad@seznam.cz (D.K.)

* Author to whom correspondence should be addressed; E-Mail: hofer@ibp.cz; Tel.: +420-541-517-171; Fax: +420-541-211-293.

Received: 12 April 2012; in revised form: 4 May 2012 / Accepted: 8 May 2012 / Published: 10 May 2012

Abstract: The presented review summarizes experimental data obtained with a mouse model when investigating the relationship between inhibition of prostaglandin production and hematopoiesis. While prostaglandin E2 acts in a negative feedback control of myelopoiesis, inhibition of cyclooxygenases, responsible for its production, shifts the feedback to positive control. Based on these relationships, agents inhibiting cyclo-oxygenases, known as non-steroidal anti-inflammatory drugs (NSAIDs), can activate hematopoiesis and be protective or curative under myelosuppressive states. The effectiveness of therapeutic use of NSAIDs in these situations is expressive especially under the selective inhibition of cyclooxygenase-2 (COX-2), when undesirable side effects of cyclooxygenase-1 inhibition, like gastrointestinal damage, are absent. The effects of the clinically approved selective COX-2 inhibitor, meloxicam, were investigated and demonstrated significant hematopoiesis-stimulating and survival-enhancing actions of this drug in sublethally or lethally γ-irradiated mice. These effects were connected with the ability of meloxicam to increase serum levels of the granulocyte colony-stimulating factor. It can be inferred from these findings that selective COX-2 inhibitors might find their use in the treatment of myelosuppressions of various etiologies.

Keywords: prostaglandins; cyclooxygenase inhibition; cyclooxygenase-2 inhibitors; hematopoiesis; myelosuppression
1. Introduction

Hematopoiesis is an intricate complex of processes through which functional blood cells of several lineages are produced. These processes take place in hematopoietic tissues which are a compartmentalized system of cells undergoing proliferation and differentiation during their development from stem cells through progenitor and precursor cells resulting in production of mature blood cells. These proliferation and differentiation processes are regulated by a number of growth factors, cytokines and other molecules [1,2].

Among these molecules and processes, an important role is played by prostaglandins and by inhibition of their production via the action of cyclooxygenases. Cyclooxygenases, also known as prostaglandin H-2 synthases, are heme-containing enzymes which catalyze the first committed step in prostaglandin synthesis. They catalyze two distinct reactions, namely cyclization of arachidonic acid to form prostaglandin G2 and hydroperoxidation of prostaglandin G2 to form prostaglandin H2 [3–5]. Prostaglandin H2 is subsequently converted to biologically active products including, among others, prostaglandin E2 (PGE2), which participates in the regulation of hematopoiesis and plays an important role in the negative hematopoietic feedback control [6–11]. On the other hand, inhibition of PGE2 production shifts the regulatory balance to positive control. Due to these mechanisms the pharmacological inhibition of cyclooxygenases by agents known as non-steroidal anti-inflammatory drugs (NSAIDs) offers the possibility to positively influence hematopoietic functions. NSAIDs are employed clinically not only for treatment of inflammatory states [12], but also in other indications like the prevention [13] and treatment of cancer [14]. The possibilities of cancer treatment may be closely related to hematological effects of cyclooxygenase inhibitors, summarized in this review, because the suppression of hematopoiesis belongs to frequent undesirable side effects of oncological therapy utilizing cytotoxic drugs. These aspects substantiate investigation of hematopoiesis-modulating action of cyclooxygenase inhibitors in experimental studies.

It should be mentioned that PGE2 was reported to promote hematopoietic stem cell proliferation [15], as well as stem cell renewal and engraftment [16,17]. These findings seem to be in contradiction to numerous findings on suppressor effects of PGE2 on hematopoiesis and on hematopoiesis-stimulating action of cyclooxygenase inhibitors. Their explanation in connection with the reported stimulatory effects of NSAIDs may consist in the fact that the hematopoietic stem cells compartment does not play a determinant role in the time period of the lowest hematopoietic depression following a myelo-suppressive intervention. In these situations the condition of the more differentiated compartments of hematopoietic progenitor and precursor cells plays a key role in regeneration of hematopoiesis. Moreover, the described PGE2-induced enhanced stem cell renewal [16,17] may reflect a decreased outflow of cells to the more differentiated compartments where their presence is indispensable for successful hematopoietic recovery. Timing and dosing effects of the drug administration have to be taken into account, as well.

Since cyclooxygenases carrying out prostaglandin synthesis exist in two isoforms, namely cyclooxygenase-1 (COX-1), which is expressed constitutively in a variety of tissues including the gastrointestinal tract, and cyclooxygenase-2 (COX-2), which is inducible and responsible for the production of prostaglandins during inflammatory states [18–20], two types of cyclooxygenase-inhibiting drugs can be distinguished. The first type comprises non-selective cyclooxygenase inhibitors which
Molecules 2012, 17

5617

affect both COX-1 and COX-2 [18], the second type is represented by selective COX-2 inhibitors which are devoid of the undesirable effects induced by the inhibition of COX-1 and are responsible, e.g., for gastrointestinal damage [21]. Experimental and clinical data demonstrate a reduced risk of the undesirable gastrointestinal side effects after administration of COX-2-selective inhibitors as compared with the effects induced by classical non-selective cyclooxygenase inhibitors [22].

2. Action of Non-Selective Cyclooxygenase Inhibitors on Hematopoiesis: Desirable and Undesirable Effects of the Treatments—The History

During the eighties of the last century, prostaglandins were shown to inhibit the proliferation of hematopoietic progenitor cells [6]. In addition, the administration of indomethacin, a drug belonging to the NSAID class and acting on the principle of non-selective inhibition of cyclooxygenases, was observed to induce mouse splenic erythropoiesis and to increase numbers of granulocyte-macrophage progenitor cells in bone marrow [8]. These and other findings in mice enabled formulation of the hypothesis that prostaglandins, especially those of the E type, played a negative feedback role in regulation of granulopoiesis and proliferation of more primitive hematopoietic cells [9–11]. As concerns detailed mechanisms of the effects observed, it was found that monocytes/macrophages were producers of prostaglandins as well as of regulatory cytokines and hematopoietic growth factors [23] and that the production of cytokines by macrophages could be modulated by exogenous prostaglandins [24] and by administration of NSAIDs [25,26]. These observations strongly suggested that an indirect mechanism, i.e., mediation through cells not directly involved in hematopoietic lineages directed at production of erythrocytes, granulocytes, lymphocytes or platelets, played a key role in the modulation of hematopoiesis via the regulatory feedback system mediated by prostaglandins.

Various non-selective cyclooxygenase inhibitors were reported to stimulate proliferation of hematopoietic stem cells [27], to enhance bone marrow and splenic hematopoiesis [28,29], and bone marrow erythropoiesis [30] in mice. Many studies have been performed by several research groups on the topic of experimental treatment of hematopoiesis suppressed by ionizing radiation (described in more detail in an earlier review [31]). Positive therapeutical outcomes, manifested as an enhancement of murine hematopoiesis after radiation damage, were reported when NSAIDs (indomethacin, diclofenac, or flurbiprofen) were administered before [32–35] or after irradiation [36–38], as well as when given to mice exposed to fractionated irradiation [39–41], to continuously irradiated rats [42], or lethally irradiated mice who received syngeneic bone marrow transplantation [43,44]. Administration of diclofenac was found to stimulate hematopoiesis also in tumor-bearing mice [45] and NSAIDs were observed to improve the processes of hematopoietic regeneration following exposures of experimental mice to ionizing radiation when administered concomitantly with immunomodulators glucan [46,47], muramyl tripeptide phosphatidylethanolamine [48–50], or broncho-vaxom [51,52], as well as with chemical radioprotectors cystamine or WR-2721 [53–56]. An improvement of hematopoietic recovery after administration of non-selective cyclooxygenase inhibitors was also observed in mice whose bone marrow was damaged by cytotoxic anti-tumor drugs [57–59]. The above-mentioned studies have shown that non-selective inhibitors of cyclooxygenases enhance a wide spectrum of hematological parameters in experimental animals, ranging from multipotent progenitor cells to mature blood cells.
However, as already briefly stated in the Introduction, it is known from experimental investigations [60] as well as from clinical observations [61] that administration of non-selective cycloxygenase inhibitors, called sometimes classical NSAIDs, is frequently accompanied by undesirable side effects, especially those in the gastrointestinal tract. These effects arise from the ability of prostaglandins to act cytoprotectively in the gastrointestinal mucosa [62]. In connection with the above-summarized findings of stimulatory effects of classical NSAIDs on radiation-suppressed hematopoiesis, it should be mentioned that these observations were carried out after sublethal irradiation inducing a pure bone marrow syndrome of the acute radiation disease without any serious damage to the gastrointestinal tract. However, after exposure to lethal radiation doses, damaging both the bone marrow and the gastrointestinal tissues, a reduced survival and appearance of early deaths were found in mice treated with classical NSAIDs either before [63] or after irradiation [64]. Histological examination revealed pathological changes in the NSAIDs-treated mice, including a partial loss of intestinal epithelium [64]. With the aim to obtain NSAIDs with reduced gastrointestinal side effects, a number of derivatives of classical NSAIDs were synthesized and tested. It was found out that a nitroderivative of commonly clinically used NSAID flurbiprofen, flurbiprofen 4-nitroxybutylester [65], exhibiting reduced ulcerogenic properties, retained the hematopoiesis-stimulating effectiveness of the original drug and enhanced insignificantly survival after lethal irradiation [66].

The results obtained in studies on hematological and/or radioprotective effects of non-selective cyclooxygenase inhibitors have been evaluated by Michalowski [67] who summarized that “Further studies on anti-inflammatory drug treatment of radiation damage to normal organs are justified and desirable”.

3. Action of Selective Cyclooxygenase-2 Inhibitors on Hematopoiesis: Desired Shift in the Treatment Outcome—Recent Findings

Because of the low incidence and intensity of their gastrointestinal side effects, selective COX-2 inhibitors also became interesting for investigation of their possible hematopoiesis-stimulating action. If they retained the stimulatory effectiveness of the classical NSAIDs, they could be used advantageously in the treatment of both main indications of myelosuppression, namely in patients with the bone marrow suppression induced by radiation exposure and in those with the hematopoiesis damaged by cytotoxic anti-cancer drugs.

First attempts to evaluate the hematopoiesis-modulating abilities of the selective COX-2 inhibition were performed in the 1990’s when a significant increase in counts of total white blood cells and neutrophils in experimentally burned rats treated with the selective COX-2 inhibitor NS-398 was reported [68].

During the last six years, a promising aggregate of findings has been accumulated indicating the hematopoiesis- and survival-modulating action of meloxicam, another clinically available selective COX-2 inhibitor [69]. In 2006, the authors of this review published their findings showing that meloxicam stimulates both granulopoiesis and erythropoiesis in mice receiving the drug either in a single dose before whole-body irradiation with a dose of 6.5 Gy $\gamma$-rays or repeatedly (four times) after irradiation with a dose of 4 Gy [70]. Another study has shown that meloxicam given to mice either singly or repeatedly after a sublethal irradiation increases the level of serum granulocyte colony-stimulating
factor (G-CSF) [71]; thus, the induction of G-CSF production by meloxicam can be considered an important mechanism of its hematopoiesis-stimulating effectiveness. Positive effects of administration of meloxicam on radiation-suppressed hematopoiesis have been confirmed also by investigations of mice irradiated with mid-lethal doses of 7.50 or 7.75 Gy γ-rays; a significantly improved survival and significant elevation of important hematological parameters in mice administered the selective COX-2 inhibitor 1 h before irradiation has been recorded [72]. The ability of meloxicam to elevate serum G-CSF levels has been confirmed in this study as well. Jiao et al. [73] have brought attention to the loss of survival-enhancing effects of meloxicam if the drug was administered repeatedly (seven times) in the post-irradiation period following a lethal radiation exposure. However, our recent studies [74] have demonstrated that a mere single dose of meloxicam given to mice shortly (1 h) after a lethal irradiation is sufficient for obtaining the desirable survival-increasing effects. Also this simple pharmacological treatment has been accompanied by an elevation of serum G-CSF [74]. The loss of positive effects of meloxicam after its repeated post-irradiation administration [73] can be evoked by vascular [75] or hepatic [76] side effects of meloxicam which can manifest themselves easily under the conditions of a serious post-irradiation stress. On the other hand, the positive effect of the single early post-irradiation injection of meloxicam [74] is in agreement with the demand for a very early post-irradiation therapeutic intervention, as proposed by Hérodin and Drouet [77,78]. Meloxicam has been shown to act positively also in a combined treatment regimen when given in a single early post-irradiation dose followed by two post-irradiation injections of IB-MECA, an adenosine A3 receptor agonist [79]. Taken together, the results of the studies on the action of the selective inhibitor of cyclooxygenase-2, meloxicam, clearly show that this drug retains the hematopoiesis-stimulating effects of the classical NSAIDs but shows much less undesirable side effects and, thus, they strongly suggest the possibility of its use in the treatment of radiation-induced myelosuppression.

As concerns the mechanisms of meloxicam action, the described ability of meloxicam to elevate serum levels of G-CSF bears evidence for the assumption that meloxicam does not stimulate hematopoietic cells directly but that at least a part of its stimulatory effects on proliferation of hematopoietic progenitor and precursor cells is indirect, mediated through its interaction with G-CSF-producing cells. A seemingly contradictory finding on the role of PGE2 and production of G-CSF was reported concerning the ability of PGE2 to stimulate LPS-primed G-CSF release from mouse peritoneal neutrophils [80]. However, the authors of this report themselves interpret their finding as a result of regulation of local production of G-CSF during an acute inflammation, which represents an expressive difference in comparison with our observations of a system G-CSF elevation and action achieved by administration of a COX-2 inhibitor.

4. Notes on the Use of Meloxicam in Anti-Tumor Therapy in Connection with Its Hematopoiesis-Stimulating Action

Meloxicam has been repeatedly reported to show anti-tumor activities [81–86]. With regard to the above-summarized findings of stimulatory effects of meloxicam on radiation-suppressed hematopoiesis, it is justified to assume that meloxicam should similarly support also hematopoiesis damaged by cytotoxic drugs. Nevertheless, further investigations testing this assumption are needed. Induction of combined anti-tumor and hematopoiesis-stimulating effects in one drug would be very advantageous.
Moreover, the effects of combined administration of meloxicam or other selective COX-2 inhibitors with hematopoietic growth factors (e.g., G-CSF) should be studied in detail, as well. G-CSF is a rather costly drug [87]. The above-mentioned findings bearing evidence of the ability of meloxicam to induce the production of G-CSF [71,72,74] suggest that a part of the total dose of G-CSF could be substituted by a cheaper drug like meloxicam.

5. Conclusions

Based on the results presented in this review, its authors are of the opinion that clinical studies on hematological effects of meloxicam or other selective COX-2 inhibitors should be commenced. An extension of indications for administration of selective COX-2 inhibitors to those of myelosuppressions of various etiologies is desirable.

Acknowledgments

This work was supported by the Grant Agency of the Czech Republic (grants Nos. 305/08/0158 and P303/11/0128) and by the Ministry of Defense of the Czech Republic (project “Receptor”, project No. 1001 8 5090).

References

1. Kaushansky, K.; Lichtman, M.; Beutler, E.; Kipps, T.; Prchal, J.; Seligsohn, U. *Williams Hematology*, 8th ed.; McGraw-Hill, Inc.: New York, NY, USA, 2010.
2. Zion, L.I. *Hematopoiesis: A Developmental Approach*; Oxford University Press: New York, NY, USA, 2001.
3. Brady, R.H.; Serhan, C.N. The prostaglandin, leukotrienes, lipoxins, and platele-activating factor. In *Immunology and Inflammation, Basic Mechanisms and Clinical Consequences*; McGraw-Hill, Inc.: New York, NY, USA, 1993; pp. 271–286.
4. Smith, W.L.; DeWitt, D.L.; Garavito, R.M. Cyclooxygenases: Structural, cellular, and molecular biology. *Annu. Rev. Biochem.* 2000, 68, 145–182.
5. Garavito, R.M.; Mulichak, A.M. The structure of mammalian cyclooxygenases. *Annu. Rev. Biophys. Biomol. Struct.* 2003, 32, 183–206.
6. Gentile, P.; Byer, D.; Pelus, L.M. *In vivo* modulation of murine myelopoiesis following intravenous administration of prostaglandin E₂. *Blood* 1983, 62, 1100–1107.
7. Pelus, L.M.; Broxmeyer, H.E.; Kurland, J.I.; Moore, M.A.S. Regulation of macrophage and granulocyte proliferation. Specificities of prostaglandin E and lactoferrin. *J. Exp. Med.* 1979, 150, 277–292.
8. Boorman, G.A.; Luster, M.I.; Dean, J.H.; Luebke, R.W. Effect of indomethacin on the bone marrow and immune system of the mouse. *J. Clin. Lab. Immunol.* 1982, 7, 119–126.
9. Kurland, J.; Moore, M.A.S. Modulation of hemopoiesis by prostaglandins. *Exp. Hematol.* 1977, 5, 357–373.
10. Fontagné, J.; Adolphe, M.; Semichon, M.; Zizine, L.; Lechat, P. Effect of *in vivo* treatment with indomethacin on mouse granulocyte-macrophage colony-forming cells in culture (CFUc). Possible role of prostaglandins. *Exp. Hematol.* **1980**, *8*, 1157–1164.

11. Pelus, L.M. Modulation of myelopoiesis by prostaglandin E₂: Demonstration of a novel mechanism of action *in vivo*. *Immunol. Res.* **1989**, *8*, 176–184.

12. Maravic, M.; Berge, C.; Daures, J.P.; Boissier, M.C. Practices for managing a flare of long-standing rheumatoid arthritis: Survey among French rheumatologists. *Clin. Exp. Rheumatol.* **2005**, *23*, 36–42.

13. Harris, R.E.; Beebe-Donk, J.; Doss, H.; Doss, D.B. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade. *Oncol. Rep.* **2005**, *13*, 559–583.

14. Peregr. D.; Lishner, M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. *J. Int. Med.* **2005**, *248*, 115–123.

15. Fehér, I.; Gidáli, J. Prostaglandin E₂ as stimulator of haemopoietic stem cell proliferation. *Nature* **1974**, *247*, 550–551.

16. North, T.E.; Goessling, W.; Walkley, C.R.; Lengerke, C.; Kopani, K.R.; Lord, A.M.; Weber, G.J.; Bowman, T.V.; Jang, I.H.; Grosser, T.; *et al.* Prostaglandin E₂ regulates vertebrate haematopoietic stem cell homeostasis. *Nature* **2007**, *447*, 1007–1011.

17. Hogatt, J.; Singh, P.; Sampaik, J.; Pelus, L.M. Prostaglandin E-2 enhances hematopoietic stem cell homing, survival, and proliferation. *Blood* **2009**, *113*, 5444–5455.

18. Frölich, J.C. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. *Trends Pharmacol. Sci.* **1997**, *18*, 30–34.

19. Simmons, D.L.; Botting, R.M.; Hla, T. Cyclooxygenase isoenzymes: The biology of prostaglandin synthesis and inhibition. *Pharmacol. Rev.* **2004**, *56*, 387–437.

20. Smith, W.L.; Urade, Y.; Jakobsson, P.-J. Enzymes of the cyclooxygenase pathways of prostanoid synthesis. *Chem. Rev.* **2011**, *111*, 5821–5865.

21. Crofford, L.J.; Lipsky, P.E.; Brooks, P.; Abramson, S.B.; Simon, L.S.; van de Putte, L.B.A. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. *Arthritis Rheum.* **2000**, *43*, 4–13.

22. Lanas, A.; Panés, J.; Piqué, J.M. Clinical implications of COX-1 and/or COX/2 inhibition for the distal gastrointestinal tract. *Curr. Pharm. Des.* **2003**, *9*, 2253–2266.

23. Niho, Y.; Niido, H.; Tanaka, Y.; Nakshima, H.; Otsuka, T. Role of IL-10 in the crossregulation of prostaglandins and cytokines in monocytes. *Acta Haematol.* **1998**, *99*, 165–170.

24. Takahashi, H.K.; Iwagaki, H.; Tamura, R.; Xue, D.; Sano, M.; Mori, S.; Yoshino, T.; Tanaka, N.; Nishibori, M. Unique regulation profile of prostaglandin E-1 on mononuclear cells. *J. Pharmacol. Exp. Therap.* **2003**, *307*, 1188–1195.

25. Chang, D.M.; Baptiste, P.; Chur, P.H. The effect of antirheumatic drugs on interleukin-1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes. *J. Rheumatol.* **1990**, *17*, 1148–1157.

26. Lozanski, G.; Ballou, S.P.; Kushner, I. Effect of flurbiprofen on cytokine production by human monocytes and U-937 and THP-1 cell-lines. *J. Rheumatol.* **1992**, *19*, 921–926.

27. Estrov, Z.; Resnitzky, P. Enhancement of hemopoietic stem cell proliferation by prostaglandin inhibitor drugs. *Exp. Hematol.* **1983**, *11*, 802–809.
28. Boorman, G.A.; Luster, M.I.; Dean, J.H.; Luebke, R.W. Effect of indomethacin on the bone marrow and immune system of the mouse. *J. Clin. Lab. Immunol.* 1982, 7, 119–126.

29. Taniguchi, K.; Koga, Y.; Kato, M.; Nomoto, K. The *in vivo* regulation of splenic T cell population by the prostaglandin-mediated system. *J. Clin. Lab. Immunol.* 1984, 14, 195–203.

30. Kalaidjieva, V. Modulation of erythropoiesis in rat bone marrow erythroblastic islands by cyclooxygenase inhibition. *Gen. Pharmacol.* 1999, 32, 423–428.

31. Hofer, M.; Pospíšil, M. Stimulated recovery of perturbed haematopoiesis by inhibition of prostaglandin production—Promising therapeutic strategy. *Cent. Eur. J. Biol.* 2006, 1, 584–593.

32. Furuta, Y.; Hunter, N.; Barkley, T.; Hall, E.; Milas, L. Increase in radioresponse of murine tumors by treatment with indomethacin. *Cancer Res.* 1988, 48, 3008–3013.

33. Kozubík, A.; Pospíšil, M.; Netíková, J. The stimulatory effect of single-dose pre-irradiation administration of indomethacin and diclofenac on hematopoietic recovery in the spleen of gamma-irradiated mice. *Stud. Biophys.* 1989, 131, 93–101.

34. Nishiguchi, I.; Furuta, Y.; Hunter, N.; Murray, D.; Milas, L. Radioprotection of hematopoietic tissue by indomethacin. *Radiat. Res.* 1990, 122, 188–192.

35. Kozubík, A.; Hofmanová, J.; Holá, J.; Netíková, J. The effect of nordihydroguaiaretic acid, an inhibitor of prostaglandin and leukotriene biosynthesis, on hematopoiesis of gamma-irradiated mice. *Exp. Hematol.* 1993, 21, 138–142.

36. Pospíšil, M.; Netíková, J.; Kozubík, A. Enhancement of haemopoietic recovery by indomethacin after sublethal whole-body gamma irradiation. *Acta Radiol. Oncol.* 1986, 25, 195–198.

37. Pospíšil, M.; Netíková, J.; Kozubík, A.; Pipalová, I. Effect of indomethacin, diclofenac sodium and sodium salicylate on peripheral blood cell counts in sublethally gamma-irradiated mice. *Strahlenther. Onkol.* 1989, 165, 627–631.

38. Serushago, B.A.; Tanaka, K.; Koga, Y.; Taniguchi, K.; Nomoto, K. Positive effects of indomethacin on restoration of splenic nucleated cell population in mice given sublethal irradiation. *Immunopharmacology* 1987, 14, 21–26.

39. Sklobovskaya, I.E.; Zhavoronkov, L.P.; Dubovik, R.V. Haemostimulating efficiency of prostaglandin biosynthesis inhibitors in conditions of fractionated irradiation (in Russian). *Radiobiologiya* 1986, 26, 185–188.

40. Hofer, M.; Pospíšil, M.; Pipalová, I. Radioprotective effects of flurbiprofen. *Folia Biol. (Praha)* 1996, 42, 267–269.

41. Hofer, M.; Pospíšil, M.; Pipalová, I.; Holá, J. Modulation of haemopoietic radiation response of mice by diclofenac in fractionated treatment. *Physiol. Res.* 1996, 45, 213–220.

42. Mišúrová, E.; Kropáčková, K.; Chlebovský, O.; Pado, D. The effect of indomethacin on nucleic acids in blood, hemopoietic and lymphoid tissues in continuously irradiated rats. *Neoplasma* 1989, 36, 541–547.

43. Kozubík, A.; Pospíšil, M.; Viklická, Š.; Tkadleček, L.; Netíková, J. Effect of indomethacin on the proliferation and differentiation activity in the haemopoietic system of lethally irradiated mice after syngeneic bone marrow transplantation. *Folia Biol. (Praha)* 1987, 33, 418–423.

44. Kozubík, A.; Hofmanová, J.; Pospíšil, M.; Netíková, J.; Holá, J.; Lojek, A. Effects of drugs inhibiting prostaglandin or leukotriene biosynthesis on postirradiation haematopoiesis in mice. *Int. J. Radiat. Biol.* 1994, 65, 369–377.
45. Hofer, M.; Hoferová, Z.; Fedoročko, P.; Macková, N.O. Hematopoiesis-stimulating and anti-tumor effects of repeated administration of diclofenac in mice with transplanted fibrosarcoma cells. *Physiol. Res.* **2002**, *51*, 629–632.

46. Pospíšil, M.; Hofer, M.; Pipalová, I.; Viklická, Š.; Netíková, J.; Šandula, J. Enhancement of hematopoietic recovery in gamma-irradiated mice by the joint use of diclofenac, an inhibitor of prostaglandin production, and glucan, a macrophage activator. *Exp. Hematol.* **1992**, *20*, 891–895.

47. Hofer, M.; Pospíšil, M.; Viklická, Š.; Vacek, A.; Pipalová, I.; Bartoníčková, A. Hematopoietic recovery in repeatedly irradiated mice can be enhanced by a repeatedly administered combination of diclofenac and glucan. *J. Leukoc. Biol.* **1993**, *53*, 185–189.

48. Fedoročko, P. Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) promotes hematopoietic recovery in irradiated mouse. *Int. J. Radiat. Biol.* **1994**, *65*, 465–475.

49. Fedoročko, P.; Macková, N.O. Combined modality radioprotection: Enhancement of survival and hematopoietic recovery by the joint use of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and indomethacin. *Int. J. Immunopharmacol.* **1996**, *18*, 329–337.

50. Macková, N.O.; Fedoročko, P. Effect of liposomal muramyl tripeptide phosphatidylethanolamine and indomethacin on hematopoietic recovery in irradiated mice. *Physiol. Res.* **2002**, *51*, 511–521.

51. Fedoročko, P.; Macková, N.O.; Brezani, P.; Kopka, M. Administration of the bacterial extract Broncho-Vaxom(R) enhances radiation recovery and myelopoietic regeneration. *Immunopharmacology* **1994**, *28*, 163–170.

52. Fedoročko, P.; Macková, N.O. Radioprotective effects of combination of bronchovaxom, a macrophage activator, and indomethacin, an inhibitor of prostaglandin production: Relationships to myelopoiesis. *Eur. J. Haematol.* **1996**, *56*, 54–61.

53. Sklobovskaya, I.E.; Zhavoronkov, L.P. The combined effect of chemical radioprotective agents and prostaglandin biosynthesis inhibitors on postirradiation recovery of mouse haemopoiesis (in Russian). *Radioobiologiya* **1986**, *26*, 61–64.

54. Kozubík, A.; Pospíšil, M.; Netíková, J. Enhancement of haemopoietic recovery in sublethally gamma-irradiated mice by the joint use of indomethacin and cystamine. *Folia Biol. (Praha)* **1990**, *36*, 291–300.

55. Kozubík, A.; Pospíšil, M.; Netíková, J. Possibilities of the combined use of non-steroidal anti-inflammatory drugs and sulfhydryl compounds in radioprotection. *Strahlenther. Onkol.* **1991**, *167*, 186–190.

56. Besa, P.C.; Hunter, N.R.; Milas, L. Improvement in radiotherapy for a murine sarcoma by indomethacin plus WR-2721. *Radiat. Res.* **1993**, *135*, 93–97.

57. Fontagné, J.; Bertin, R.; Demarco, F.; Zizine, L.; Adolphe, M.; Portet, R.; Lechat, P. *In vivo* effects of indomethacin and cyclophosphamide on CFU-GM proliferation and cyclic-nucleotide levels in bone marrow of mice. *Biomed. Pharmacol.* **1983**, *37*, 452–457.

58. Nickevich, D.A.; Young, M.R.; Ellis, N.K.; Wepsich, H.T. Stimulation of hematopoiesis in untreated and cyclophosphamide-treated mice by the inhibition of prostaglandin synthesis. *J. Immunopharmacol.* **1986**, *8*, 299–313.

59. O’Reilly, M.; Gamelli, R.L. Indomethacin augments granulocyte-macrophage colony-stimulating factor-induced hematopoiesis following 5-FU treatment. *Exp. Hematol.* **1990**, *18*, 974–978.
60. Wang, J.Y.; Yamasaki, S.; Takeuchi, K.; Okabe, S. Delayed healing of acetic acid-induced gastric ulcers in rats by indomethacin. *Gastroenterology* 1989, 96, 393–402.

61. Akareia, U.S. Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs. *Curr. Pharm. Des.* 2005, 11, 1779–1793.

62. Mahmud, T.; Scott, D.L.; Bjarnason, I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. *Ann. Rheum. Dis.* 1996, 55, 211–213.

63. Floersheim, G.L. Allopurinol, indomethacin and riboflavin enhance radiation lethality in mice. *Radiat. Res.* 1994, 139, 240–247.

64. Hofer, M.; Pospíšil, M.; Tkadleček, L.; Viklická, Š.; Pipalová, I. Low survival of mice following lethal gamma-irradiation after administration of inhibitors of prostaglandin synthesis. *Physiol. Res.* 1992, 41, 157–161.

65. Wallace, J.L.; Reuter, B.; Cicala, C.; McKnight, W.; Grisham, M.B.; Cirino, G. Novel nonsteroidal antiinflammatory drug derivatives with markedly reduced ulcerogenic properties in rats. *Gastroenterology* 1994, 107, 173–179.

66. Juchelková, L.; Hofer, M.; Pospíšil, M.; Pipalová, I. Radioprotective effects of flurbiprofen and its nitroderivative. *Physiol. Res.* 1998, 47, 73–80.

67. Michalowski, A.S. On radiation damage to normal tissues and its treatment. II. Anti-inflammatory drugs. *Acta Oncol.* 1994, 33, 139–157.

68. Shoup, M.; He, L.K.; Liu, H.; Shankar, R.; Gamelli, R. Cyclooxygenase-2 inhibitor NS-398 improves survival and restores leukocyte counts in burn infection. *J. Trauma Inj. Infect Crit. Care* 1998, 45, 215–220.

69. Ogino, K.; Hatanaka, K.; Kawamura, M.; Ohno, T.; Harada, Y. Meloxicam inhibits prostaglandin E2 generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach. *Pharmacology* 2000, 61, 244–250.

70. Hofer, M.; Pospíšil, M.; Znojil, V.; Holá, J.; Vacek, A.; Weiterová, L.; Štreitová, D.; Kozubík, A. Meloxicam, a cyclooxygenase-2 inhibitor, supports hematopoietic recovery in gamma-irradiated mice. *Radiat. Res.* 2006, 166, 556–560.

71. Hofer, M.; Pospíšil, M.; Znojil, V.; Holá, J.; Vacek, A.; Štreitová, D. Meloxicam, an inhibitor of cyclooxygenase-2, increases the level of serum G-CSF and might be usable as an auxiliary means in G-CSF therapy. *Physiol. Res.* 2008, 57, 307–310.

72. Hofer, M.; Pospíšil, M.; Holá, J.; Vacek, A.; Štreitová, D.; Znojil, V. Inhibition of cyclooxygenase 2 in mice increases production of G-CSF and induces radioprotection. *Radiat. Res.* 2008, 170, 566–571.

73. Jiao, W.; Kiang, J.G.; Cary, L.; Elliot, T.B.; Pellmar, T.C.; Ledney, G.D. COX-2 inhibitors are contraindicated for treatment of combined injury. *Radiat. Res.* 2009, 172, 686–697.

74. Hofer, M.; Pospíšil, M.; Dušek, L.; Hoferová, Z.; Weiterová, L. A single dose of an inhibitor of cyclooxygenase 2, meloxicam, administered shortly after irradiation increases survival of lethally irradiated mice. *Radiat. Res.* 2011, 176, 269–272.

75. Anning, P.B.; Coles, B.; Morton, J.; Wang, H.; Uddin, J.; Morrow, J.D.; Dey, S.K.; Marnett, L.J.; O’Donnell, V.B. Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. *Blood* 2006, 108, 4059–4062.

76. Staerkel, P.; Horsmans, Y. Meloxicam-induced liver toxicity. *Acta Gastroenterol. Belg.* 1999, 62, 255–256.
77. Hérodin, F.; Drouet, M. Cytokine-based treatment of accidentally irradiated victims and new approaches. *Exp. Hematol.* **2005**, *33*, 1071–1080.

78. Hérodin, F.; Drouet, M. Myeloprotection following cytotoxic damage: The sooner, the better. *Exp. Hematol.* **2008**, *36*, 769–770.

79. Hofer, M.; Pospíšil, M.; Dušek, L.; Hoferová, Z.; Weiterová, L. Inhibition of cyclooxygenase-2 promotes the stimulatory action of adenosine A3 receptor agonist in sublethally γ-irradiated mice. *Biomed. Pharmacother.* **2011**, *65*, 427–431.

80. Sugimoto, Y.; Fukada, Y.; Mori, D.; Tanaka, S.; Yamane, H.; Okuno, Y.; Deai, K.; Tsuchiya, S.; Tsujimoto, G.; Ichikawa, A. Prostaglandin E-2 stimulated granulocyte colony-stimulating factor production via the prostanoid EP2 receptor in mouse peritoneal neutrophils. *J. Immunol.* **2005**, *175*, 2606–2612.

81. Goldman, A.P.; Williams, C.S.; Sheng, H.M.; Lamps, L.W.; Williams, V.P.; Pairet, M.; Morrow, J.D.; DuBois, R.N. Meloxicam inhibits the growth of colorectal cancer cells. *Carcinogenesis* **1998**, *19*, 2195–2199.

82. Hussey, H.J.; Tisdale, M.J. Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model. *Int. J. Cancer* **2000**, *87*, 95–100.

83. Kern, M.A.; Schöneweiß, M.M.; Sahi, D.; Bahlo, M.; Haugg, A.M.; Kasper, H.U.; Dienes, H.P.; Käferstein, H.; Breuhahn, K.; Schirmbacher, P. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. *Carcinogenesis* **2004**, *25*, 1193–1199.

84. Kuipers, G.K.; Slotman, B.J.; Wedekind, L.E.; Stoter, T.R.; van der Berg, J.; Sminia, P.; Vincent, M.; Lafleur, M. Radiosenzitization of human glioma cells by cyclooxygenase-2 (COX-2) inhibition: Independent on COX-2 expression and dependent on the COX-2 inhibitor and sequence of administration. *Int. J. Radiat. Biol.* **2007**, *83*, 677–685.

85. Ayakawa, S.; Shibamoto, Y.; Sugie, C.; Ito, M.; Ogino, H.; Tomito, N.; Kumagai, M.; Murakami, H.; Sawa, H. Antitumor effects of a cyclooxygenase-2 inhibitor, meloxicam, alone or in combination with radiation and/or 5-fluorouracil in cultured tumor cells. *Mol. Med. Rep.* **2009**, *2*, 621–625.

86. Crook, J.; Patil, N.; Wallace, K.; Borg, J.; Zhou, D.; Ma, C.; Pond, G. A phase III randomized trial of the timing of meloxicam with iodine-125 prostate brachytherapy. *Int. J. Radiat. Oncol. Biol. Phys.* **2010**, *77*, 496–501.

87. Lefrere, F.; Makke, J.; Fermand, J.P.; Marolleau, J.P.; Dal Cortivo, L.; Alberti, C.; Mouton, V.; Benbunan, M.; Miclea, J.M. Blood stem cell collection using chemotherapy with or without G-CSF: Experience in 52 patients with multiple myeloma. *Bone Marrow Transplant.* **1999**, *24*, 463–466.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).